Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
AstraZeneca
Bristol-Myers Squibb
National Cancer Institute (NCI)
Hoffmann-La Roche
Gilead Sciences
AstraZeneca
Nektar Therapeutics
Gilead Sciences
Children's Oncology Group
Merck Sharp & Dohme LLC
Children's Oncology Group
CTI BioPharma
Boehringer Ingelheim
GOG Foundation
Novartis
New Mexico Cancer Research Alliance
Merck KGaA, Darmstadt, Germany